Synthesis and Reactivity of Potential Toxic Metabolites of Tamoxifen Analogues: Droloxifene and Toremifene o-Quinones
- 27 November 2001
- journal article
- research article
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 14 (12), 1643-1653
- https://doi.org/10.1021/tx010137i
Abstract
Tamoxifen remains the endocrine therapy of choice in the treatment of all stages of hormone-dependent breast cancer. However, tamoxifen has been shown to increase the risk of endometrial cancer which has stimulated research for new effective antiestrogens, such as droloxifene and toremifene. In this study, the potential for these compounds to cause cytotoxic effects was investigated. One potential cytotoxic mechanism could involve metabolism of droloxifene and toremifene to catechols, followed by oxidation to reactive o-quinones. Another cytotoxic pathway could involve the oxidation of 4-hydroxytoremifene to an electrophilic quinone methide. Comparison of the amounts of GSH conjugates formed from 4-hydroxytamoxifen, droloxifene, and 4-hydroxytoremifene suggested that 4-hydroxytoremifene is more effective at formation of a quinone methide. However, all three substrates formed similar amounts of o-quinones. Both the tamoxifen-o-quinone and toremifene-o-quinone reacted with deoxynucleosides to give corresponding adducts. However, the toremifene-o-quinone was shown to be considerably more reactive than the tamoxifen-o-quinone in terms of both kinetic data as well as the yield and type of deoxynucleoside adducts formed. Since thymidine formed the most abundant adducts with the toremifene-o-quinone, sufficient material was obtained for characterization by 1H NMR, COSY-NMR, DEPT-NMR, and tandem mass spectrometry. Cytotoxicity studies with tamoxifen, droloxifene, 4-hydroxytamoxifen, 4-hydroxytoremifene, and their catechol metabolites were carried out in the human breast cancer cell lines S30 and MDA-MB-231. All of the metabolites tested showed cytotoxic effects that were similar to the parent antiestrogens which suggests that o-quinone formation from tamoxifen, droloxifene, and 4-hydroxytoremifene is unlikely to contribute to their cytotoxicity. However, the fact that the o-quinones formed adducts with deoxynucleosides in vitro implies that the o-quinone pathway might contribute to the genotoxicity of the antiestrogens in vivo.Keywords
This publication has 16 references indexed in Scilit:
- Effects of the Antiestrogens Tamoxifen, Toremifene, and ICI 182,780 on Endometrial Cancer GrowthJNCI Journal of the National Cancer Institute, 1998
- Studies on the mechanism of hepatotoxicity of 4-methylphenol (p-cresol): effects of deuterium labeling and ring substitutionChemico-Biological Interactions, 1996
- A study of the structural basis of the carcinogenicity of tamoxifen, toremifene and their metabolitesMutation research. Reviews in mutation research, 1996
- New Highly Stereoselective Synthesis of (Z)-4-Hydroxytamoxifen and (Z)-4-Hydroxytoremifene via McMurry ReactionThe Journal of Organic Chemistry, 1996
- Conformational Studies and Electronic Structures of Tamoxifen and Toremifene and Their Allylic Carbocations Proposed as Reactive Intermediates Leading to DNA Adduct FormationJournal of Medicinal Chemistry, 1996
- Preclinical data for DroloxifeneCancer Letters, 1994
- High-performance liquid chromatographic analysis of tamoxifen, toremifene and their major human metabolitesJournal of Chromatography B: Biomedical Sciences and Applications, 1993
- Pharmacologic and Biologic Properties of Droloxifene, A New AntiestrogenAmerican Journal of Clinical Oncology, 1991
- Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituentJournal of Medicinal Chemistry, 1989
- Stereochemistry and Reactions with Hydroxyl Ion and with Silver Oxide of the 2-Bromo-4-phenylcyclohexanols and the 1-Methyl-2-bromo-4-phenylcyclohexanols1Journal of the American Chemical Society, 1960